[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Guangzhou Wondfo Biotech Co., Ltd.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":76},{"warningLetters":4,"total":75},[5,33,54],{"id":6,"raw":7,"subject":14,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":28,"body_fetched_at":29,"delivery_method":30,"recipient_title":20,"reference_number":31,"action_taken_date":32,"medical_device_id":20,"response_letter_date":20},986,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-03-25T04:00:00Z\">03\u002F25\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-10-07T04:00:00Z\">10\u002F07\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhangzhou-glamcos-biotech-co-ltd-692583-10072024\">Hangzhou Glamcos Biotech Co., Ltd.\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FUnapproved New Drug\u003Cbr \u002F>\r\n","","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FUnapproved New Drug","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-02\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ai Hong Ruan\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Hangzhou Glamcos Biotech Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No 288 Xiufeng Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tonglu Xian\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hangzhou Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Zhejiang Sheng\u003C\u002Fspan>, \u003Cspan>311500\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-02\u003C\u002Fp>\u003Cp>October 7, 2024\u003Cbr>\u003Cbr>Dear Ai Hong Ruan:\u003C\u002Fp>\u003Cp>Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our March 4, 2024 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, Hangzhou Glamcos Biotech Co., Ltd., FEI 3017053743, at No 288 Xiufeng Road Tonglu County, Hangzhou, Zhejiang, China.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\u003Cp>In addition, “disinpro multi-purpose ANTIBACTERIAL WIPES” is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act,) 21 U.S.C. 355(a) and 331(d). This product is also misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Additionally, “disinpro multi-purpose ANTIBACTERIAL WIPES” and “Antibacterial Wet Wipes” are misbranded under section 502(f)(2) of the FD&amp;C Act, 21 U.S.C. 352(f)(2). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant violations were observed including, but not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>CGMP Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the records and information you provided, you did not demonstrate you conducted adequate finished drug product testing on your drug products before releasing them for distribution.\u003C\u002Fp>\u003Cp>Full release testing, including strength and identity testing of the active ingredient, must be performed before drug product release and distribution. Without adequate testing, you do not have adequate scientific evidence to assure your drug products conform to appropriate specifications before release.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactured OTC drug products including antibacterial wet wipes used for reducing bacteria on skin. Based on the records and information you provided, you did not demonstrate you adequately performed identity testing on incoming components including, but not limited to, glycerin and propylene glycol, which are at high-risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination. Identity testing for these and certain other high-risk drug components\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> include a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform sufficient identity testing, you failed to assure the acceptability of these components for use in manufacture of your drug products.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\u003Cp>We also note your active pharmaceutical ingredient supplier does not appear to be registered with the FDA, and the information you provided does not indicate you have adequately qualified your raw material suppliers.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the stability records and information you provided, you did not demonstrate the quality attributes of your drug products remain acceptable throughout the labeled expiry period. For example, you did not include active ingredient testing as part of your stability program.\u003C\u002Fp>\u003Cp>Without appropriate stability studies, you do not have scientific evidence to support whether your drug products meet established specifications and retain their quality attributes through their labeled expiry.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the records and information you provided, your batch production records were inadequate. For example, your batch production records for OTC drug products lacked documentation that each significant step in the manufacture, processing, packing, or holding of the batch was accomplished.\u003C\u002Fp>\u003Cp>Without adequate and complete batch records, you cannot assure the uniformity of your drug products from batch to batch and may impact your ability to adequately investigate any product deviations.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved New Drug Violations and Misbranded Drug Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on their labeled intended uses, “disinpro multi-purpose ANTIBACTERIAL WIPES” and “Antibacterial Wet Wipes” are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, these products are intended for use as consumer antiseptic rub drug products.\u003C\u002Fp>\u003Cp>Examples from the “disinpro multi-purpose ANTIBACTERIAL WIPES” and “Antibacterial Wet Wipes” product labeling that provide evidence of the intended uses (as defined in 21 CFR 201.128) of these products include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>“\u003Cu>disinpro multi-purpose ANTIBACTERIAL WIPES\u003C\u002Fu>”\u003Cbr>“Drug Facts…Use: For handwashing to decrease bacteria on the skin. Kills 99.9% of germs.” [from the product label]\u003C\u002Fp>\u003Cp>“\u003Cu>Antibacterial Wet Wipes\u003C\u002Fu>”\u003Cbr>“Drug Facts…Use: For handwashing to decrease bacteria on the skin.” [from the product label]\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved New Drug Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>“disinpro multi-purpose ANTIBACTERIAL WIPES” is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&amp;C Act (which not the case for this product, as further described below) or other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your “disinpro multi-purpose ANTIBACTERIAL WIPES” drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>We note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016) (2016 Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use in a consumer antiseptic rub.\u003C\u002Fp>\u003Cp>Section 505G of the FD&amp;C Act addresses nonprescription drugs marketed without an approved application. Under 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\u003C\u002Fp>\u003Cp>However, “disinpro multi-purpose ANTIBACTERIAL WIPES” does not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505. Specifically, the label states that “disinpro multi-purpose ANTIBACTERIAL WIPES” contain benzalkonium chloride at a concentration of 0.2%; however, benzalkonium chloride is only permitted at a concentration of 0.1% to 0.13%.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of this unapproved new drug product into interstate commerce violates sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Misbranded Drug Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The “disinpro multi-purpose ANTIBACTERIAL WIPES” and “Antibacterial Wet Wipes” drug products are misbranded under section 502(f)(2) of the FD&amp;C Act, 21 U.S.C. 352(f)(2), because the product labels do not include all of the applicable warnings required under 21 CFR 330.1(g). Specifically, the labels do not include the complete warning statement that reads, “If swallowed, get medical help or contact a Poison Control Center right away.”\u003C\u002Fp>\u003Cp>Additionally, “disinpro multi-purpose ANTIBACTERIAL WIPES” is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because this product is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Additional Concerns\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We note that the “disinpro multi-purpose ANTIBACTERIAL WIPES” and “Antibacterial Wet Wipes” drug products are marketed as “antiseptic wipes.” Antiseptic wipes generally refer to consumer antiseptic rub drug products that are not intended to be rinsed-off after use. However, the labels for both products suggests that they can be used as a consumer antiseptic wash. For example, both labels state, “For hand washing to decrease bacteria on the skin.” An antiseptic wipe drug product marketed under section 505G of the FD&amp;C Act cannot also be a consumer antiseptic wash, as the directions for use conflict with each other and a wipe is not an acceptable dosage form for an antiseptic wash.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>\u003Cstrong>Discrepancy in Information Provided\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In response to FDA’s initial records request, you asserted that you have not manufactured drugs for the United States in three years. After FDA provided you information regarding shipments of drugs from your facility as recent as of January 8, 2024, you then provided the requested information. FDA is concerned that you may have falsely alleged that you do not manufacture, process, pack, or hold drugs for the United States.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Production\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In response to this letter, clarify whether you intend to continue to manufacture drugs for the U.S. market at this facility in the future.\u003C\u002Fp>\u003Cp>If you plan to resume any manufacturing operations regulated under the FD&amp;C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all corrective action and preventive action (CAPA).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>FDA placed your firm on Import Alert 66-40 on September 30, 2024.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Hangzhou Glamcos Biotech Co., Ltd. at No 288 Xiufeng Road Tonglu County, Hangzhou, Zhejiang, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3017053743 and ATTN: Matthew Jensen.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>__________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Components with higher risk of DEG or EG contamination compared to other drug components.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> The permitted dosage forms for consumer antiseptic washes are set forth here: “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use,” Proposed Rule, 78 FR 76444 (December 17, 2013) and “OTC Safety and Effectiveness of Topical Antimicrobial Drug Products for Over-the Counter Human Use,” Final Rule, 81 FR 61106 (September 6, 2016).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> See section IV of the FDA Guidance for Industry Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug or Device Inspection at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86328\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> i.e. Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nReference #:\n\n320-25-02\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nAi Hong Ruan\n\nRecipient Title\n\nGeneral Manager\n\nHangzhou Glamcos Biotech Co., Ltd.\n\nNo 288 Xiufeng Road\n\nTonglu Xian\n\nHangzhou Shi\n\nZhejiang Sheng, 311500\n\nChina\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-02\nOctober 7, 2024\n\nDear Ai Hong Ruan:\nYour facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our March 4, 2024 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Hangzhou Glamcos Biotech Co., Ltd., FEI 3017053743, at No 288 Xiufeng Road Tonglu County, Hangzhou, Zhejiang, China.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 351(a)(2)(B)).\nIn addition, “disinpro multi-purpose ANTIBACTERIAL WIPES” is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act,) 21 U.S.C. 355(a) and 331(d). This product is also misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Additionally, “disinpro multi-purpose ANTIBACTERIAL WIPES” and “Antibacterial Wet Wipes” are misbranded under section 502(f)(2) of the FD&C Act, 21 U.S.C. 352(f)(2). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed including, but not limited to, the following:\nCGMP Violations\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\nBased on the records and information you provided, you did not demonstrate you conducted adequate finished drug product testing on your drug products before releasing them for distribution.\nFull release testing, including strength and identity testing of the active ingredient, must be performed before drug product release and distribution. Without adequate testing, you do not have adequate scientific evidence to assure your drug products conform to appropriate specifications before release.\n2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYour firm manufactured OTC drug products including antibacterial wet wipes used for reducing bacteria on skin. Based on the records and information you provided, you did not demonstrate you adequately performed identity testing on incoming components including, but not limited to, glycerin and propylene glycol, which are at high-risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination. Identity testing for these and certain other high-risk drug components1 include a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform sufficient identity testing, you failed to assure the acceptability of these components for use in manufacture of your drug products.\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\nWe also note your active pharmaceutical ingredient supplier does not appear to be registered with the FDA, and the information you provided does not indicate you have adequately qualified your raw material suppliers.\n3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\nBased on the stability records and information you provided, you did not demonstrate the quality attributes of your drug products remain acceptable throughout the labeled expiry period. For example, you did not include active ingredient testing as part of your stability program.\nWithout appropriate stability studies, you do not have scientific evidence to support whether your drug products meet established specifications and retain their quality attributes through their labeled expiry.\n4. Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).\nBased on the records and information you provided, your batch production records were inadequate. For example, your batch production records for OTC drug products lacked documentation that each significant step in the manufacture, processing, packing, or holding of the batch was accomplished.\nWithout adequate and complete batch records, you cannot assure the uniformity of your drug products from batch to batch and may impact your ability to adequately investigate any product deviations.\nUnapproved New Drug Violations and Misbranded Drug Violations\nBased on their labeled intended uses, “disinpro multi-purpose ANTIBACTERIAL WIPES” and “Antibacterial Wet Wipes” are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, these products are intended for use as consumer antiseptic rub drug products.\nExamples from the “disinpro multi-purpose ANTIBACTERIAL WIPES” and “Antibacterial Wet Wipes” product labeling that provide evidence of the intended uses (as defined in 21 CFR 201.128) of these products include, but may not be limited to, the following:\n“disinpro multi-purpose ANTIBACTERIAL WIPES”\n“Drug Facts…Use: For handwashing to decrease bacteria on the skin. Kills 99.9% of germs.” [from the product label]\n“Antibacterial Wet Wipes”\n“Drug Facts…Use: For handwashing to decrease bacteria on the skin.” [from the product label]\nUnapproved New Drug Violations\n“disinpro multi-purpose ANTIBACTERIAL WIPES” is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&C Act (which not the case for this product, as further described below) or other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your “disinpro multi-purpose ANTIBACTERIAL WIPES” drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nWe note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016) (2016 Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use in a consumer antiseptic rub.\nSection 505G of the FD&C Act addresses nonprescription drugs marketed without an approved application. Under 505G(a)(3) of the FD&C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\nHowever, “disinpro multi-purpose ANTIBACTERIAL WIPES” does not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505. Specifically, the label states that “disinpro multi-purpose ANTIBACTERIAL WIPES” contain benzalkonium chloride at a concentration of 0.2%; however, benzalkonium chloride is only permitted at a concentration of 0.1% to 0.13%.\nThe introduction or delivery for introduction of this unapproved new drug product into interstate commerce violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nMisbranded Drug Violations\nThe “disinpro multi-purpose ANTIBACTERIAL WIPES” and “Antibacterial Wet Wipes” drug products are misbranded under section 502(f)(2) of the FD&C Act, 21 U.S.C. 352(f)(2), because the product labels do not include all of the applicable warnings required under 21 CFR 330.1(g). Specifically, the labels do not include the complete warning statement that reads, “If swallowed, get medical help or contact a Poison Control Center right away.”\nAdditionally, “disinpro multi-purpose ANTIBACTERIAL WIPES” is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because this product is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nAdditional Concerns\nWe note that the “disinpro multi-purpose ANTIBACTERIAL WIPES” and “Antibacterial Wet Wipes” drug products are marketed as “antiseptic wipes.” Antiseptic wipes generally refer to consumer antiseptic rub drug products that are not intended to be rinsed-off after use. However, the labels for both products suggests that they can be used as a consumer antiseptic wash. For example, both labels state, “For hand washing to decrease bacteria on the skin.” An antiseptic wipe drug product marketed under section 505G of the FD&C Act cannot also be a consumer antiseptic wash, as the directions for use conflict with each other and a wipe is not an acceptable dosage form for an antiseptic wash.2\nDiscrepancy in Information Provided\nIn response to FDA’s initial records request, you asserted that you have not manufactured drugs for the United States in three years. After FDA provided you information regarding shipments of drugs from your facility as recent as of January 8, 2024, you then provided the requested information. FDA is concerned that you may have falsely alleged that you do not manufacture, process, pack, or hold drugs for the United States.3\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit4 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nDrug Production\nIn response to this letter, clarify whether you intend to continue to manufacture drugs for the U.S. market at this facility in the future.\nIf you plan to resume any manufacturing operations regulated under the FD&C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all corrective action and preventive action (CAPA).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nFDA placed your firm on Import Alert 66-40 on September 30, 2024.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Hangzhou Glamcos Biotech Co., Ltd. at No 288 Xiufeng Road Tonglu County, Hangzhou, Zhejiang, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated or misbranded may be detained or refused admission.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3017053743 and ATTN: Matthew Jensen.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n__________________\n1 Components with higher risk of DEG or EG contamination compared to other drug components.\n2 The permitted dosage forms for consumer antiseptic washes are set forth here: “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use,” Proposed Rule, 78 FR 76444 (December 17, 2013) and “OTC Safety and Effectiveness of Topical Antimicrobial Drug Products for Over-the Counter Human Use,” Final Rule, 81 FR 61106 (September 6, 2016).\n3 See section IV of the FDA Guidance for Industry Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug or Device Inspection at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86328\u002Fdownload.\n4 i.e. Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","Hangzhou Glamcos Biotech Co., Ltd.","hangzhou-glamcos-biotech-co-ltd-692583-10072024","2026-08-18T06:42:28.676509+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhangzhou-glamcos-biotech-co-ltd-692583-10072024","2026-10-26T08:08:52.445351+00:00","Warning Letter","Issued","2025-03-25","692583","Drugs","Ai Hong Ruan","2026-08-19T16:55:11.131+00:00","Via Email","320-25-02","2024-10-07",{"id":34,"raw":35,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":20,"letter_url":45,"updated_at":46,"action_type":23,"case_status":24,"posted_date":47,"marcs_cms_no":48,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":49,"body_fetched_at":50,"delivery_method":51,"recipient_title":20,"reference_number":52,"action_taken_date":53,"medical_device_id":20,"response_letter_date":20},160,[36,37,38,11,39,13,13,13],"\u003Ctime datetime=\"2026-05-19T04:00:00Z\">05\u002F19\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-04-15T04:00:00Z\">04\u002F15\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhangzhou-yiqi-biotechnology-co-ltd-720707-04152026\">Hangzhou Yiqi Biotechnology Co., Ltd  \u003C\u002Fa>","CGMP\u002FActive Pharmaceutical Ingredient (API)\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL WITH READ RECEIPT\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-66\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Jack Chai\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Hangzhou Yiqi Biotechnology Co., Ltd  \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Room 204, Building 3, No. 66 Xixiang Road, Puyan Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hangzhou Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Zhejiang Sheng\u003C\u002Fspan>, \u003Cspan>310018\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-66\u003C\u002Fp>\u003Cp>April 15, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Chai:\u003C\u002Fp>\u003Cp>Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of active pharmaceutical ingredients (APIs). FDA has reviewed the records you submitted in response to our June 16, 2025, request and subsequent correspondence, for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, Hangzhou Yiqi Biotechnology Co., Ltd, FEI 3035145155, at Room 204, Building 3, No. 66 Xixiang Road, Puyan Street, Hangzhou, Zhejiang 310018, China.\u003C\u002Fp>\u003Cp>This Warning Letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for APIs.\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant deviations were observed including, but not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to demonstrate that your manufacturing process can reproducibly manufacture an API meeting its predetermined quality attributes.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the records and information you provided, your firm failed to conduct process validation for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> APIs manufactured at your facility. These APIs are for use in further processing to produce sterile drug products and for pharmaceutical compounding operations.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its life cycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\u003Cp>Without adequate process validation, your firm lacks basic assurance that you can reproducibly deliver products that meet specifications. See FDA’s guidance for industry \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that the FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\u003Cli>A timeline for performing appropriate process performance qualification for each of your marketed APIs.\u003C\u002Fli>\u003Cli>Also provide a risk assessment and any follow up actions to be taken for the distributed APIs produced without performing any process validation studies.\u003C\u002Fli>\u003Cli>Process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\u003Cli>A detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Failure to validate and verify the suitability of analytical methods.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the records and information you provided, your firm failed to perform test method validation or verification for each test method used for drugs distributed to the United States.\u003C\u002Fp>\u003Cp>Test methods must be validated to show that they are suitable for their intended use or verified to show at least equivalence with United States Pharmacopeia (USP) compendial methods. Method validation and verification are necessary to support reliable determinations of identity, strength, quality, purity, and potency of drugs. Without evaluating the validity of methods, you lack the basic assurance that the data provided to customers were an accurate reflection of pharmaceutical product quality and safety.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>A list of chemical and microbial test methods and specifications used to analyze each lot of your APIs before making a lot of disposition decisions, and the associated written procedures.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Failure to design a documented, ongoing stability testing program to monitor the stability characteristics of API and to use the results to confirm appropriate storage conditions and retest or expiry dates.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the records and information you provided, your firm failed to perform routine stability testing to demonstrate that the quality attributes of your APIs remain acceptable throughout the labeled expiry period. For example, your firm did not provide sufficient stability test data for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, or other APIs manufactured at your facility.\u003C\u002Fp>\u003Cp>Without an appropriate stability program, you lack adequate scientific evidence to support that your APIs meet established specifications and retain their quality attributes throughout their labeled expiry.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A retrospective risk assessment showing how you will ensure that marketed APIs meet stability specifications throughout their shelf life.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include but should not be limited to:\u003Cbr>o Stability indicating methods\u003Cbr>o Stability studies for each API in its marketed container\u002Fclosure system before distribution is permitted\u003Cbr>o An ongoing program in which representative lots of each product are added each year to the program to determine if the shelf-life claim remains valid\u003Cbr>o A detailed definition of the specific attributes to be tested at each station (time point)\u003Cbr>o All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Failure to demonstrate that water used in the manufacture of your API is suitable for its intended use.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the records and information you provided, you failed to demonstrate that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system is adequately monitored to ensure that it consistently produces water suitable for use in the manufacture of APIs intended for further processing into sterile drug products.\u003C\u002Fp>\u003Cp>Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system must be adequately designed and properly maintained to minimize and control the potential for contamination. It must be suitable for its intended use and routinely tested at an adequate frequency to ensure ongoing conformance with appropriate chemical and microbiological attributes.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A procedure for monitoring your water system that specifies routine microbial testing of water to ensure its acceptability for use in each lot of APIs produced by your firm.\u003C\u002Fli>\u003Cli>The current action\u002Falert levels for total counts and objectionable organisms used for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water system.\u003C\u002Fli>\u003Cli>A procedure governing your program for ongoing control, maintenance, and monitoring to ensure that the remediated system consistently produces water that meets \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water, USP monograph specifications and appropriate microbial limits.\u003C\u002Fli>\u003Cli>Test methods, water-analysis frequency, diagrams of the water system, and the location of all sampling points.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Additional API CGMP Guidance\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA considers the expectations outlined in ICH Q7 when determining whether API are manufactured in conformance with CGMP. \u003Cem>See FDA’s guidance document Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients\u003C\u002Fem> for guidance regarding CGMP for the manufacture of API at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71518\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered from your firm for import into the United States on Import Alert 66-40 on January 30, 2026.\u003C\u002Fp>\u003Cp>Correct any deviations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may verify that you have completed corrective actions to any deviations.\u003C\u002Fp>\u003Cp>Failure to address any deviations may also result in the FDA’s continuing to refuse admission of articles manufactured at Hangzhou Yiqi Biotechnology Co., Ltd, No. 66 Xixiang Road, Puyan Street, Hangzhou, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated or misbranded may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B), and are misbranded under section 502 of the FD&amp;C Act, respectively.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3935145155 and ATTN: Chhaya Shetty.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL WITH READ RECEIPT\n\nReference #:\n\n320-26-66\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Jack Chai\n\nRecipient Title\n\nGeneral Manager\n\nHangzhou Yiqi Biotechnology Co., Ltd\n\nRoom 204, Building 3, No. 66 Xixiang Road, Puyan Street\n\nHangzhou Shi\n\nZhejiang Sheng, 310018\n\nChina\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-66\nApril 15, 2026\nDear Mr. Chai:\nYour facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of active pharmaceutical ingredients (APIs). FDA has reviewed the records you submitted in response to our June 16, 2025, request and subsequent correspondence, for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Hangzhou Yiqi Biotechnology Co., Ltd, FEI 3035145155, at Room 204, Building 3, No. 66 Xixiang Road, Puyan Street, Hangzhou, Zhejiang 310018, China.\nThis Warning Letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for APIs.\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant deviations were observed including, but not limited to, the following:\n1. Failure to demonstrate that your manufacturing process can reproducibly manufacture an API meeting its predetermined quality attributes.\nBased on the records and information you provided, your firm failed to conduct process validation for the (b)(4) APIs manufactured at your facility. These APIs are for use in further processing to produce sterile drug products and for pharmaceutical compounding operations.\nProcess validation evaluates the soundness of design and state of control of a process throughout its life cycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\nWithout adequate process validation, your firm lacks basic assurance that you can reproducibly deliver products that meet specifications. See FDA’s guidance for industry Process Validation: General Principles and Practices for general principles and approaches that the FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\nIn response to this letter, provide:\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\nA timeline for performing appropriate process performance qualification for each of your marketed APIs.\nAlso provide a risk assessment and any follow up actions to be taken for the distributed APIs produced without performing any process validation studies.\nProcess performance protocol(s), and written procedures for qualification of equipment and facilities.\nA detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\n2. Failure to validate and verify the suitability of analytical methods.\nBased on the records and information you provided, your firm failed to perform test method validation or verification for each test method used for drugs distributed to the United States.\nTest methods must be validated to show that they are suitable for their intended use or verified to show at least equivalence with United States Pharmacopeia (USP) compendial methods. Method validation and verification are necessary to support reliable determinations of identity, strength, quality, purity, and potency of drugs. Without evaluating the validity of methods, you lack the basic assurance that the data provided to customers were an accurate reflection of pharmaceutical product quality and safety.\nIn response to this letter, provide:\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nA list of chemical and microbial test methods and specifications used to analyze each lot of your APIs before making a lot of disposition decisions, and the associated written procedures.\n3. Failure to design a documented, ongoing stability testing program to monitor the stability characteristics of API and to use the results to confirm appropriate storage conditions and retest or expiry dates.\nBased on the records and information you provided, your firm failed to perform routine stability testing to demonstrate that the quality attributes of your APIs remain acceptable throughout the labeled expiry period. For example, your firm did not provide sufficient stability test data for (b)(4), or other APIs manufactured at your facility.\nWithout an appropriate stability program, you lack adequate scientific evidence to support that your APIs meet established specifications and retain their quality attributes throughout their labeled expiry.\nIn response to this letter, provide:\nA retrospective risk assessment showing how you will ensure that marketed APIs meet stability specifications throughout their shelf life.\nA comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include but should not be limited to:\no Stability indicating methods\no Stability studies for each API in its marketed container\u002Fclosure system before distribution is permitted\no An ongoing program in which representative lots of each product are added each year to the program to determine if the shelf-life claim remains valid\no A detailed definition of the specific attributes to be tested at each station (time point)\no All procedures that describe these and other elements of your remediated stability program.\n4. Failure to demonstrate that water used in the manufacture of your API is suitable for its intended use.\nBased on the records and information you provided, you failed to demonstrate that your (b)(4) water system is adequately monitored to ensure that it consistently produces water suitable for use in the manufacture of APIs intended for further processing into sterile drug products.\nYour (b)(4) water system must be adequately designed and properly maintained to minimize and control the potential for contamination. It must be suitable for its intended use and routinely tested at an adequate frequency to ensure ongoing conformance with appropriate chemical and microbiological attributes.\nIn response to this letter, provide:\nA procedure for monitoring your water system that specifies routine microbial testing of water to ensure its acceptability for use in each lot of APIs produced by your firm.\nThe current action\u002Falert levels for total counts and objectionable organisms used for your (b)(4) Water system.\nA procedure governing your program for ongoing control, maintenance, and monitoring to ensure that the remediated system consistently produces water that meets (b)(4) Water, USP monograph specifications and appropriate microbial limits.\nTest methods, water-analysis frequency, diagrams of the water system, and the location of all sampling points.\nAdditional API CGMP Guidance\nFDA considers the expectations outlined in ICH Q7 when determining whether API are manufactured in conformance with CGMP. See FDA’s guidance document Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients for guidance regarding CGMP for the manufacture of API at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71518\u002Fdownload.\nConclusion\nThe deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\nFDA placed all drugs and drug products offered from your firm for import into the United States on Import Alert 66-40 on January 30, 2026.\nCorrect any deviations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may verify that you have completed corrective actions to any deviations.\nFailure to address any deviations may also result in the FDA’s continuing to refuse admission of articles manufactured at Hangzhou Yiqi Biotechnology Co., Ltd, No. 66 Xixiang Road, Puyan Street, Hangzhou, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated or misbranded may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B), and are misbranded under section 502 of the FD&C Act, respectively.\nThis letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3935145155 and ATTN: Chhaya Shetty.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Hangzhou Yiqi Biotechnology Co., Ltd","hangzhou-yiqi-biotechnology-co-ltd-720707-04152026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhangzhou-yiqi-biotechnology-co-ltd-720707-04152026","2026-10-26T08:08:52.533347+00:00","2026-05-19","720707","Mr. Jack Chai","2026-08-19T04:41:17.242+00:00","VIA EMAIL WITH READ RECEIPT","320-26-66","2026-04-15",{"id":55,"raw":56,"subject":60,"body_html":61,"body_text":62,"firm_name":63,"letter_id":64,"created_at":65,"fei_number":20,"letter_url":66,"updated_at":67,"action_type":23,"case_status":24,"posted_date":68,"marcs_cms_no":69,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":70,"body_fetched_at":71,"delivery_method":72,"recipient_title":20,"reference_number":73,"action_taken_date":74,"medical_device_id":20,"response_letter_date":20},1151,[57,58,59,11,60,13,13,13],"\u003Ctime datetime=\"2024-11-26T14:20:00Z\">11\u002F26\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-11-18T05:00:00Z\">11\u002F18\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhangzhou-huiji-biotechnology-co-ltd-692844-11182024\">Hangzhou Huiji Biotechnology Co., Ltd.\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-16\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Zhan Libin\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Hangzhou Huiji Biotechnology Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No. 3 Shunshuiqiao Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Renhe Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Yuhang Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hangzhou Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Zhejiang Sheng\u003C\u002Fspan>, \u003Cspan>310012\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-16\u003C\u002Fp>\n\n\u003Cp>November 18, 2024\u003Cbr>\n\u003Cbr>\nDear Mr. Libin:\u003C\u002Fp>\n\n\u003Cp>Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our March 4, 2024 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, Hangzhou Huiji Biotechnology Co., Ltd., FEI 3010461961, at No. 3 Shunshuiqiao Road, Renhe Street, Yuhang District, Hangzhou, Zhejiang.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>704(a)(4) Request for Records and Related CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant violations were observed including, but not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm manufactures OTC drug products, including gel hand sanitizers containing ethyl alcohol. Based on the records and information you provided, you did not demonstrate that you adequately tested the identity of incoming components used in the manufacture of your drug products. For example, in your response, you state that you do not verify the identity of each shipment of drug ingredients prior to use in manufacturing. Additionally, you state that you do not utilize appropriate raw material tests described in USP, including the limit tests for DEG\u002FEG and methanol, despite your records indicating that you manufacture products containing glycerin and ethanol.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Glycerin\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Information provided indicates that you failed to adequately test each shipment of each lot of glycerin for identity, a component at higher risk for diethylene glycol (DEG) and ethylene glycol (EG) contamination. We note that glycerin is an ingredient used in your hand sanitizer drug products. Identity testing for glycerin and certain other high-risk drug components\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> include a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Ethanol\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You failed to adequately test your incoming ethanol, which is used as an active ingredient in your hand sanitizer, for methanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ethanol at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>Without adequate testing, you do not have scientific evidence that your components conform to appropriate specifications prior to use in the manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on the records and information you provided, you did not demonstrate that you adequately tested your finished drug products for the identity and strength of the active ingredient, ethanol prior to release and distribution. For example, the “content of ethanol solutes” test procedure that you provided is not an appropriate laboratory determination of the identity and strength of your ethanol active ingredient. Additionally, you did not demonstrate the suitability of this test procedure per 21 CFR 211.165(e).\u003C\u002Fp>\n\n\u003Cp>Testing is an essential part of CGMP to ensure that the drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use. Drug products must be tested for identity and strength of the active ingredient, prior to release and distribution. Without adequate testing, you do not have scientific evidence to assure that your drug products conform to appropriate specifications before release.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The records and information you provided, demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. For example, your QU failed to ensure that appropriate batch production records were used during the manufacturing of your drug products. Your QU also failed to ensure that adequate stability data supported the expiry of your drug products. In addition, your QU failed to ensure that your water system used in the manufacture of your OTC hand sanitizers, is appropriately designed and monitored in light of its intended use.\u003C\u002Fp>\n\n\u003Cp>Your QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may not be conducting appropriate oversight regarding CGMP operations.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Cosmetics Manufactured for Distribution in the United States\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In addition, we note that some of the drug products you manufacture may also be regulated as cosmetics, as defined in section 201(i) of the FD&amp;C Act. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&amp;C Act. Under section 301(a) of the FD&amp;C Act (21 U.S.C. 331(a)), it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded. Further, your facility may be subject to requirements of the Modernization of Cosmetic Regulations Act of 2022 (MoCRA). Information on MoCRA requirements may be found at https:\u002F\u002Fwww.fda.gov\u002Fcosmetics\u002Fcosmetics-laws-regulations\u002Fmodernization-cosmetics-regulationact-2022-mocra.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on November 15, 2024.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Hangzhou Huiji Biotechnology Co., Ltd., No. 3 Shunshuiqiao Road, Renhe Street, Yuhang District, Hangzhou Zhejiang, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3017005720 and ATTN: Daniel W. Brisker.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>Cc:\u003Cbr>\nRegistered U.S. Agent\u003Cbr>\nJames H Liao\u003Cbr>\nPrincipal\u003Cbr>\nApax International Inc.\u003Cbr>\njames@sino2us.com\u003C\u002Fp>\n\n\u003Cp>_____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Components with higher risk of DEG or EG contamination compared to other drug components.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-25-16\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Zhan Libin\n\nRecipient Title\n\nGeneral Manager\n\nHangzhou Huiji Biotechnology Co., Ltd.\n\nNo. 3 Shunshuiqiao Road\n\nRenhe Street\n\nYuhang Qu\n\nHangzhou Shi\n\nZhejiang Sheng, 310012\n\nChina\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-16\n\nNovember 18, 2024\n\nDear Mr. Libin:\n\nYour facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our March 4, 2024 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Hangzhou Huiji Biotechnology Co., Ltd., FEI 3010461961, at No. 3 Shunshuiqiao Road, Renhe Street, Yuhang District, Hangzhou, Zhejiang.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B)).\n\n704(a)(4) Request for Records and Related CGMP Violations\n\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed including, but not limited to, the following:\n\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\n\nYour firm manufactures OTC drug products, including gel hand sanitizers containing ethyl alcohol. Based on the records and information you provided, you did not demonstrate that you adequately tested the identity of incoming components used in the manufacture of your drug products. For example, in your response, you state that you do not verify the identity of each shipment of drug ingredients prior to use in manufacturing. Additionally, you state that you do not utilize appropriate raw material tests described in USP, including the limit tests for DEG\u002FEG and methanol, despite your records indicating that you manufacture products containing glycerin and ethanol.\n\nGlycerin\n\nInformation provided indicates that you failed to adequately test each shipment of each lot of glycerin for identity, a component at higher risk for diethylene glycol (DEG) and ethylene glycol (EG) contamination. We note that glycerin is an ingredient used in your hand sanitizer drug products. Identity testing for glycerin and certain other high-risk drug components1 include a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\n\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\n\nEthanol\n\nYou failed to adequately test your incoming ethanol, which is used as an active ingredient in your hand sanitizer, for methanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol to help you meet the CGMP requirements when manufacturing drugs containing ethanol at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\n\nWithout adequate testing, you do not have scientific evidence that your components conform to appropriate specifications prior to use in the manufacture of your drug products.\n\n2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\n\nBased on the records and information you provided, you did not demonstrate that you adequately tested your finished drug products for the identity and strength of the active ingredient, ethanol prior to release and distribution. For example, the “content of ethanol solutes” test procedure that you provided is not an appropriate laboratory determination of the identity and strength of your ethanol active ingredient. Additionally, you did not demonstrate the suitability of this test procedure per 21 CFR 211.165(e).\n\nTesting is an essential part of CGMP to ensure that the drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use. Drug products must be tested for identity and strength of the active ingredient, prior to release and distribution. Without adequate testing, you do not have scientific evidence to assure that your drug products conform to appropriate specifications before release.\n\n3. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\n\nThe records and information you provided, demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. For example, your QU failed to ensure that appropriate batch production records were used during the manufacturing of your drug products. Your QU also failed to ensure that adequate stability data supported the expiry of your drug products. In addition, your QU failed to ensure that your water system used in the manufacture of your OTC hand sanitizers, is appropriately designed and monitored in light of its intended use.\n\nYour QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may not be conducting appropriate oversight regarding CGMP operations.\n\nSee FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions.\n\nCosmetics Manufactured for Distribution in the United States\n\nIn addition, we note that some of the drug products you manufacture may also be regulated as cosmetics, as defined in section 201(i) of the FD&C Act. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&C Act. Under section 301(a) of the FD&C Act (21 U.S.C. 331(a)), it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded. Further, your facility may be subject to requirements of the Modernization of Cosmetic Regulations Act of 2022 (MoCRA). Information on MoCRA requirements may be found at https:\u002F\u002Fwww.fda.gov\u002Fcosmetics\u002Fcosmetics-laws-regulations\u002Fmodernization-cosmetics-regulationact-2022-mocra.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on November 15, 2024.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Hangzhou Huiji Biotechnology Co., Ltd., No. 3 Shunshuiqiao Road, Renhe Street, Yuhang District, Hangzhou Zhejiang, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3017005720 and ATTN: Daniel W. Brisker.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCc:\n\nRegistered U.S. Agent\n\nJames H Liao\n\nPrincipal\n\nApax International Inc.\n\njames@sino2us.com\n\n_____________________\n\n1 Components with higher risk of DEG or EG contamination compared to other drug components.","Hangzhou Huiji Biotechnology Co., Ltd.","hangzhou-huiji-biotechnology-co-ltd-692844-11182024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhangzhou-huiji-biotechnology-co-ltd-692844-11182024","2026-10-26T08:08:52.48141+00:00","2024-11-26","692844","Mr. Zhan Libin","2026-08-19T18:13:32.694+00:00","VIA UPS","320-25-16","2024-11-18",3,{"510k":77,"classification":78,"enforcement":79,"event":80,"event_backfill":81,"pma":82,"warning_letter":83},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]